Drug Price Trends for Cell

Average Pharmacy Cost for Cell

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
CELLCEPT 250 MG CAPSULE	00004-0259-01	8.65031	EACH	2026-07-22
CELLCEPT 250 MG CAPSULE	00004-0259-43	8.65031	EACH	2026-07-22
CELLCEPT 500 MG TABLET	00004-0260-01	17.38249	EACH	2026-07-22
CELLCEPT 500 MG TABLET	00004-0260-43	17.38249	EACH	2026-07-22
CELLCEPT 200 MG/ML ORAL SUSP	00004-0261-29	8.31829	ML	2026-07-22
CELLCEPT 250 MG CAPSULE	00004-0259-01	8.64903	EACH	2026-06-17

Best Wholesale Price for Cell

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
CELLCEPT 250MG CAP	Genentech USA, Inc.	00004-0259-01	100	886.03	8.86030	EACH	2024-01-01 - 2028-09-14	FSS
CELLCEPT 1000MG/5ML SUSP,ORAL	Genentech USA, Inc.	00004-0261-29	160ML	992.44	6.20275	ML	2023-09-15 - 2028-09-14	Big4
CELLCEPT 500MG TABLETS	Genentech USA, Inc.	00004-0260-01	100	1322.12	13.22120	EACH	2024-01-01 - 2028-09-14	Big4
CELLCEPT IV 500MG/20ML INJECTION	Genentech USA, Inc.	00004-0298-09	4X20ML	425.40			2024-01-01 - 2028-09-14	FSS
CELLCEPT 250MG CAP	Genentech USA, Inc.	00004-0259-43	500	3259.53	6.51906	EACH	2023-09-15 - 2028-09-14	Big4
CELLCEPT 1000MG/5ML SUSP,ORAL	Genentech USA, Inc.	00004-0261-29	160ML	1360.05	8.50031	ML	2023-09-15 - 2028-09-14	FSS

Last updated: July 27, 2026

Market analysis and price projections for “Cell” (active ingredient: Cell—insufficient identification)

No complete market analysis or price projections can be produced because the drug identity is not specified. “Cell” is not a unique drug name, active ingredient, dosage form, strength, route, or jurisdiction, so revenue, comparator sets, payer dynamics, and patent/regulatory timelines cannot be mapped to a specific FDA/EMA product.

Key Takeaways

• The drug name provided (“Cell”) is not uniquely identifiable for market sizing, pricing, or exclusivity/patent-based price erosion projections.
• Price forecasts require the specific labeled product (active ingredient + form/strength + market geography + regulatory status).

FAQs

1. What inputs are required to forecast launch pricing for an FDA-listed drug?
2. How do exclusivity (NCE, pediatric, REMS, patent term) affect long-term net price?
3. What is the typical magnitude of price erosion after first generic entry in the US?
4. How should biosimilar competition pricing be modeled versus small-molecule generic competition?
5. How do PBM formulary rules change expected net revenue versus WAC?

References

No sources cited.